Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection

Yankaskas, 2004, Cystic fibrosis adult care: consensus conference report, Chest, 125, 1S, 10.1378/chest.125.1_suppl.1S Rivas Caldas, 2014, Upper aero-digestive contamination by Pseudomonas aeruginosa and implications in Cystic Fibrosis, J Cyst Fibros Daines, 2014, Serology as a diagnostic tool for predicting initial Pseudomonas aeruginosa acquisition in children with cystic fibrosis, J Cyst Fibros, 13, 542, 10.1016/j.jcf.2014.06.005 Sanders, 2014, Phenotypes that matter: Pseudomonas aeruginosa and progression of cystic fibrosis lung disease, Am J Respir Crit Care Med, 190, 245, 10.1164/rccm.201406-1145ED Elizur, 2008, Airway inflammation in cystic fibrosis, Chest, 133, 489, 10.1378/chest.07-1631 Volpi, 2012, Is lung function worsening during adolescence in cystic fibrosis? A retrospective study, Eur Respir J, 40, P3370 Mayer-Hamblett, 2007, Association between pulmonary function and sputum biomarkers in cystic fibrosis, Am J Respir Crit Care Med, 175, 822, 10.1164/rccm.200609-1354OC Neri, 2012, Real-time monitoring of breath ammonia during haemodialysis: use of ion mobility spectrometry (IMS) and cavity ring-down spectroscopy (CRDS) techniques, Nephrol Dial Transplant, 27, 2945, 10.1093/ndt/gfr738 Monge, 2013, Ion mobility and liquid chromatography/mass spectrometry strategies for exhaled breath condensate glucose quantitation in cystic fibrosis studies, Rapid Commun Mass Spectrom, 27, 2263, 10.1002/rcm.6683 Sloane, 2005, Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects, Am J Respir Crit Care Med, 172, 1416, 10.1164/rccm.200409-1215OC Arrigo, 2013, High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children, Eur J Endocrinol, 168, 631, 10.1530/EJE-13-0037 Salpietro, 2013, Nasal high-mobility group box-1 protein in children with allergic rhinitis, Int Arch Allergy Immunol, 161, 116, 10.1159/000345246 Chirico, 2014, High-mobility group box 1 (HMGB1) in childhood: from bench to bedside, Eur J Pediatr, 173, 1123, 10.1007/s00431-014-2327-1 Rowe, 2008, Potential role of high-mobility group box 1 in cystic fibrosis airway disease, Am J Respir Crit Care Med, 178, 822, 10.1164/rccm.200712-1894OC Sagel, 2012, Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis, Am J Respir Crit Care Med, 186, 857, 10.1164/rccm.201203-0507OC Liou, 2012, Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis, PLoS One, 7, e42748, 10.1371/journal.pone.0042748 Rosenstein, 1998, The diagnosis of cystic fibrosis: a consensus statement. Cystic fibrosis foundation consensus panel, J Pediatr, 132, 589, 10.1016/S0022-3476(98)70344-0 Wang, 1993, Pulmonary function between 6 and 18 years of age, Pediatr Pulmonol, 15, 75, 10.1002/ppul.1950150204 Baker, 2013, Assessing exocrine pancreatic function: when the best test is not possible, J Pediatr Gastroenterol Nutr, 56, 116, 10.1097/MPG.0b013e31827e2293 Sagel, 2001, Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction, Am J Respir Crit Care Med, 164, 1425, 10.1164/ajrccm.164.8.2104075 Burns, 1998, Microbiology of sputum from patients at cystic fibrosis centers in the United States, Clin Infect Dis, 27, 158, 10.1086/514631 Fuchs, 1994, Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group, N Engl J Med, 331, 637, 10.1056/NEJM199409083311003 Liu, 2008, High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine, J Immunol, 181, 4240, 10.4049/jimmunol.181.6.4240 Gaggar, 2010, Proline-glycine-proline (PGP) and high mobility group box protein-1 (HMGB1): potential mediators of cystic fibrosis airway inflammation, Open Respir Med J, 4, 32 Abraham, 2000, Cutting edge: HMG-1 as a mediator of acute lung inflammation, J Immunol, 165, 2950, 10.4049/jimmunol.165.6.2950 Entezari, 2012, Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis, Mol Med, 18, 477, 10.2119/molmed.2012.00024 Junkins, 2014, The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections, Autophagy, 10, 538, 10.4161/auto.27750 Paul, 2004, Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis, Am J Respir Crit Care Med, 169, 719, 10.1164/rccm.200307-959OC